|
the problem, in the US at least, is that every clinical trial
is supposed to give the best care they know about and then add something to it or modify it in someway that noone is getting less than the best care they have already determined (whether for fear of lawsuits, problems getting approval of hospital human use committees, etc)
It seems most of these studies will take place in countries where few have access to get one year of therapy and thus, even if they get in the arm with a shorter course of therapy, they are better off than if they had not participated in the clinical trial or in countries where the governments have the final say on whether or not and for how long patients are treated with herceptin.
|